Company intelligence / Profile preview

Naegis Pharmaceuticals Inc.

Vancouver, British Columbia, Canada

Ownership: Private
Development stage: Other

Overview

Lead compound N0651 has demonstrated in multiple pre-clinical studies the ability to treat inflammatory diseases of both the front and back of the eye when administered either topically (by eye drops) or orally. The company recently secured financing to advance this patented compound through to approval of a US FDA Investigational New Drug (IND) application to enter a Phase 2 clinical trial[10].

Therapeutic areas: EndocrinologyOphthalmology
Modalities: Small moleculesoral and topical therapies
Industry: Biotech

Drug pipeline

1 asset

N0651

Preclinical

Beyond the preview

Go deeper on Naegis Pharmaceuticals Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naegis Pharmaceuticals Inc..

Explore the full profile